InDevR has filed a notice of an exempt offering of securities to raise $9,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, InDevR is raising $9,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Kathy Rowlen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About InDevR
InDevR is a global leader in progressive new analytical technologies that enable accelerated development and manufacturing of vaccines and other biotherapeutics. Key products include our VaxArray portfolio of our game-changing multiplexed potency assays for vaccines and the Cypher One system for digital imaging and automated interpretation of hemagglutination assays.
To learn more about InDevR, visit http://indevr.com/
Contact:
Kathy Rowlen, President and Chief Executive Officer
303-402-9100
https://www.linkedin.com/in/kathyrowlen/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.